Will ASCO Unlock Big Value in This Cancer Drug Class?
With the American Society of Clinical Oncology's annual meeting less than two weeks away, see what drug class could see big gains in the wake of new abstract data.
1 Giant Leap for MannKind
MannKind shares have jumped over the moon lately. What's behind this giant leap?
Presentation Pandemonium = 30% Pop
Why shares of Aegerion soared more than 30% today.
Sanofi and Regeneron's Latest Partnership
Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.